# US 2003/0202991 A1 · Delivery of biologically active polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0202991 A1
- Document ID: US20030202991A1
- Status: Published application
- Kind: A1
- Application number: 10/350,250
- Filed: 2003-01-22
- Published: 2003-10-30
- Earliest claimed: 1995-10-20
- Inventors: Lothar Steidler; Erik Remaut; Jeremy Mark Wells; Richard William Falla Le Page
- Web page: https://patentgrep.com/patent/US20030202991A1

## CPC

- C07K 14/55: IL-2
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/33: from Clostridium (G)
- C07K 14/5412: {IL-6}
- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N 15/746: {for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Biologically active polypeptides and/or antigens are delivered by administering to a subject a non-invasive or non-pathogenic bacterium which expresses one or more antigens or polypeptides. The non-invasive or non-pathogenic bacterium can be included in delivery systems or pharmaceutical formulations.

## Claims

### Claim 1

A method of delivering one or more antigens or biologically active polypeptides to a subject in need of same which comprises administering to the subject a non-invasive or non-pathogenic bacterium which expresses the one or more antigens or polypeptides.

### Claim 2 (depends on 1)

The method of claim 1 wherein the bacterium expresses both the one or more antigens and one or more biologically active polypeptides.

### Claim 3 (depends on 1)

The method of claim 1 wherein the biologically active polypeptide is heterologous to the bacterium.

### Claim 4 (depends on 3)

The method of claim 3 wherein the heterologous polypeptide is derived from an eukaryote or its virus, from a prokaryote or its virus, or from a virus homologous to a species of the bacterium.

### Claim 5 (depends on 1)

The method of claim 1 wherein the bacterium is a Gram-positive bacterium.

### Claim 6 (depends on 5)

The method of claim 5 wherein the Gram-positive bacterium is Listeria innocua, Staphylococcus xylosus, Staphylococcus carnosus, Streptococcus gordoni, a Lactococcus species or a Lactobacillus species.

### Claim 7 (depends on 6)

The method of claim 6 wherein the Gram-positive bacterium is Lactococcus lactis.

### Claim 8 (depends on 5)

The method of claim 5 wherein the bacterium is an attenuated strain of a Gram-positive pathogenic bacterium.

### Claim 9 (depends on 8)

The method of claim 8 wherein the bacterium is Listeria monocytogenes.

### Claim 10 (depends on 1)

The method of claim 1 wherein the biologically active polypeptide is one which is capable of functioning locally or systemically.

### Claim 11 (depends on 1)

The method of claim 1 wherein the biologically active polypeptide is one which is capable of regulating the activities of cells belonging to the immunohemopoeitic system.

### Claim 12 (depends on 1)

The method of claim 1 wherein the biologically active polypeptide is one which is capable of affecting the viability, growth and differentiation of normal or neoplastic cells in the body or affecting the immune regulation or induction of acute phase inflammatory responses to injury and infection.

### Claim 13 (depends on 1)

The method of claim 1 wherein the biologically active polypeptide is one which is capable of enhancing or inducing resistance to infection of cells and tissues mediated by chemokines acting on their target cell receptors, or the proliferation of epithelial cells or the promotion of wound healing.

### Claim 14 (depends on 1)

The method of claim 1 wherein the biologically active polypeptide modulates the expression or production of substances by cells in the body.

### Claim 15 (depends on 1)

The method of claim 1 wherein the biologically active polypeptide is insulin, growth hormone, prolactin, calcitonin, luteinishing hormone, parathyroid hormone, somatostatin, thyroid stimulating hormone or vasoactive intestinal polypeptide.

### Claim 16 (depends on 1)

The method of claim 1 wherein the biologically active polypeptide is a structural group 1 cytokine adopting an antiparallel 4α helical bundle structure such as IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11, IL-12, IL-13, GM-CSF, M-CSF, SCR, IFN-γ, EPO, G-CSF, LIF, OSM, CNTF, GH, PRL or IFNα/β.

### Claim 17 (depends on 1)

The method of claim 1 wherein the biologically active polypeptide is a structural group 2 cytokine which forms symmetric homotrimers and the subunits take up the conformation of jelly roll described for the TNF family of cytokines, the IL-1 family of cytokines, the fibroblast growth factor family, the platelet derived growth factors, transforming growth factor β or nerve growth factors.

### Claim 18 (depends on 1)

The method of claim 1 wherein the biologically active polypeptide is a structural group 3 cytokine comprising short chain α/β molecules, which are produced as transmembrane precursor molecules which each contain at least one EGF domain in the extracellular region.

### Claim 19 (depends on 1)

The method of claim 1 wherein the biologically active polypeptide is a structural group 4 cytokine which exhibits mosaic structures.

### Claim 20 (depends on 1)

The method of claim 1 wherein the biologically active polypeptide is a receptor or antagonist for a biologically active polypeptide.

### Claim 21 (depends on 1)

The method of claim 1 wherein the bacterium expresses an antigen or polypeptide which regulates the survival, growth, differentiation, effector functions or susceptibility to infection of cells or tissues.

### Claim 22 (depends on 1)

The method of claim 1 wherein the bacterium expresses an antigen or polypeptide which boosts an immune response against tumor cells or an infection colonizing a mucosal surface or adjacent or distant tissue.

### Claim 23 (depends on 1)

The method of claim 1 wherein the bacterium expresses an antigen or polypeptide which modulates the type of immune response (antibody versus cell-medicated) against a pathogenic infectious agent.

### Claim 24 (depends on 1)

The method of claim 1 wherein the bacterium expresses an antigen or polypeptide which modulates the infiltration of normal tissues with inflammatory or tumor cells.

### Claim 25 (depends on 1)

The method of claim 1 wherein the bacterium expresses an antigen or polypeptide which controls the rate of growth, rate of invasion or survival of tumor cells.

### Claim 26 (depends on 1)

The method of claim 1 wherein the bacterium expresses an antigen or polypeptide which induces apoptosis in tumor cells.

### Claim 27 (depends on 1)

The method of claim 1 wherein the bacterium expresses an antigen or polypeptide which downregulates an immune response.

### Claim 28 (depends on 1)

The method of claim 1, wherein the bacterium expresses an antigen or polypeptide which treats an allergic autoimmune or immune dysregulative disease state.

### Claim 29

A pharmaceutical formulation comprising a non-invasive or non-pathogenic bacterium having a nucleic acid construct or vector comprising one or more constitutive promoters and coding sequences for the expression of one or more antigens and/or heterologous biologically active polypeptides, and one or more pharmaceutically acceptable excipients, adjuvants, buffers, stabilizers or carriers.

### Claim 30 (depends on 29)

The pharmaceutical formulation of claim 29 as a vaccine formulation.

### Claim 31 (depends on 29)

A method of producing the pharmaceutical formulation of claim 29 which comprises the step of admixing one or more non-invasive or non-pathogenic bacteria with one or more pharmaceutically acceptable carriers.

### Claim 32

Nucleic acid comprising one or more coding sequences for one or more biologically active polypeptides and one or more coding sequences for one or more antigens wherein each coding sequence is under the control of a promoter for expression in a non-invasive or non-pathogenic bacterium.

### Claim 33 (depends on 32)

The nucleic acid of claim 32 which comprises one or more nucleic acid constructs in which the nucleic acid encoding the one or more biologically active polypeptides or antigens are under the control of appropriate regulatory sequences.

### Claim 34 (depends on 33)

The nucleic acid of claim 33 wherein the appropriate regulatory sequences are selected from promoter sequences, terminator fragments, enhancer sequences or marker genes.

### Claim 35 (depends on 33)

The nucleic acid of claim 33 wherein the one or more nucleic acid constructs comprise an artificial operon capable of generating a polycistronic RNA transcript.

### Claim 36 (depends on 32)

The nucleic acid of claim 32 wherein the promoter is a Lactococcal promoter for use in Lactococcus lactis.

### Claim 37 (depends on 32)

The nucleic acid of claim 32 which further comprises a secretory signal sequence, upstream of the coding sequence(s), for the one or more biologically active polypeptides.

### Claim 38 (depends on 37)

The nucleic acid of claim 37 wherein the secretory signal sequene is the α-amylase secretion leader of Bacillus amyloliquefaciens, the secretion leader of the Staphylokinase enzyme, leader sequences for other Bacillus enzymes or S-layer proteins or the leader sequence of the Lactococcal protein Usp45.

### Claim 39 (depends on 32)

The nucleic acid of claim 32 wherein the antigen is one capable of eliciting a protective immune response.

### Claim 40 (depends on 32)

The nucleic acid of claim 32 wherein the antigen is one where a protective immune response is accelerated, amplified or rendered of longer duration in the presence of one or more coexpressed biologically active polypeptides.

### Claim 41 (depends on 32)

A method of generating a bacterium which expresses one or more antigens or biologically active polypeptides which comprises the step of introducing into a non-invasive or non-pathogenic bacterial host cell the nucleic acid of claim 32.

### Claim 42

A non-invasive or non-pathogenic bacterium expressing (i) one or more heterologous biologically active polypeptides and (ii) one or more antigens.

### Claim 43 (depends on 32)

A non-invasive or non-pathogenic bacterium expressing (i) one or more heterologous biologically active polypeptides and (ii) one or more antigens which comprises the nucleic acid of claim 32.
